<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46520">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500628</url>
  </required_header>
  <id_info>
    <org_study_id>20150618</org_study_id>
    <nct_id>NCT02500628</nct_id>
  </id_info>
  <brief_title>Heart Rate Variability in Response to Metformin Challenge</brief_title>
  <official_title>Heart Rate Variability in Response to Metformin Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woodinville Psychiatric Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woodinville Psychiatric Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to
      familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated
      with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will
      provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then
      provide an additional sample 2 hours later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doctors need to develop tests which inexpensively and reliably evaluates brain metabolism.
      Current diagnostic tests sample other tissues which often run on different fuels (fats),
      utilize unproven and often insensitive brain imaging scanners, or sequence thousands to
      millions of base-pairs of DNA. All of these tests are expensive. None of these tests
      accurately or completely capture the interactions between the 1000s of proteins involved in
      brain metabolism.

      The investigators suspect that mathematical analysis of the resting heart rate may provide
      some insight into brain metabolism. The brain controls heart rate in response to changes in
      blood pressure and blood gases like carbon dioxide and oxygen. Tight control of heart rate
      is necessary to make sure that the brain has the right mix of fuel and air. Because the
      brain can't respond instantly to changes in its fuel supply, this system acting as a
      biological carburetor has a natural oscillatory rhythm that can be monitored just like
      frequencies on the radio.

      The investigators propose to amplify these rhythms by modestly metabolically stressing the
      brain with metformin, a inhibitor of complex 1 in the mitochondria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability (time domain)</measure>
    <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate variability (frequency domain)</measure>
    <time_frame>difference pre/post metformin ingestion (2 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (time domain)</measure>
    <time_frame>baseline study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective metformin response questionnaire</measure>
    <time_frame>2 hours after ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (frequency domain)</measure>
    <time_frame>baseline study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Mitochondrial Diseases</condition>
  <condition>Movement Disorders</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antipsychotic use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg po after baseline testing of heart rate</description>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Antipsychotic use</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        EITHER chronic neurogenic pain meeting ACR criteria for fibromyalgia or previous/current
        exposure to antipsychotic medications

        Exclusion Criteria:

          -  recent infection,

          -  renal failure,

          -  pre-existing cardiac disease,

          -  COPD,

          -  inability to participate in informed consent,

          -  lack of transport to return home from study site,

          -  severe fasting intolerance or hypoglycemia,

          -  history of stroke-alike episode,

          -  uncontrolled migraine or cyclic vomiting,

          -  diabetes on insulin or sulfonylurea,

          -  non-English speaker,

          -  medications with strong effects on baseline heart rate variability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon E Berner, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woodinville Psychiatric Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodinville Psychiatric Associates</name>
      <address>
        <city>Woodinville</city>
        <state>Washington</state>
        <zip>98072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 1, 2016</lastchanged_date>
  <firstreceived_date>July 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woodinville Psychiatric Associates</investigator_affiliation>
    <investigator_full_name>Jon Berner MD PhD</investigator_full_name>
    <investigator_title>Clinic Director</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>mitochondria</keyword>
  <keyword>complex 1</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>neurogenic pain</keyword>
  <keyword>diabetes</keyword>
  <keyword>tardive dyskinesia</keyword>
  <keyword>heart rate variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
